Mithra Pharmaceuticals
Specialists in women’s health, transforming options for women through innovation.
| EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 130 % | 41 % | 48 % | (91 %) | 151 % | 196 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (150 %) | (39 %) | 58 % | (27 %) | (1027 %) | (422 %) | 22 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 150 % | (76 %) | (18 %) | (28 %) | (1020 %) | (516 %) | (89 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 170 % | 104 % | 55 % | 59 % | 869 % | 376 % | 96 % |
Source: Company filings or news article
Related Content
Mithra is a Belgian biotech company specializing in women's health, particularly in the areas of contraception and menopause. The company leverages its proprietary Estetrol E4, a native estrogen produced during pregnancy, to develop innovative healthcare solutions. Mithra serves a global market, targeting healthcare providers and patients seeking advanced options for women's health. The business model revolves around research and development, clinical trials, and the commercialization of its unique estrogen-based products. Revenue is generated through product sales, licensing agreements, and partnerships with pharmaceutical companies. Mithra's commitment to innovation and science positions it as a leader in the biotech sector, aiming to transform women's health through groundbreaking solutions.
Keywords: biotech, women's health, contraception, menopause, Estetrol E4, innovation, healthcare, clinical trials, pharmaceutical partnerships, estrogen-based products.